If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
55
results.
Updated on
01/05/2025 [06:45:00]
Results 25 to 50 of 55
Absstract of: WO2025077315A1
Provided are an anti-BCMA single-domain antibody, and a preparation method therefor and the use thereof. Specifically, provided is a single-domain antibody having an amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity, can thoroughly specifically target BCMA-positive cells, and can be applied to the detection of BCMA expression in bone marrow cells of MM patients. The single-domain antibody can be prepared into a specific antibody drug clinically used for preventing and treating BCMA-target-related diseases (such as multiple myeloma, B-cell acute lymphoblastic leukemia, non-Hodgkin's lymphoma and Hodgkin's lymphoma); or a BCMA protein detection kit, etc. The single-domain antibody has a stable structure, a small molecular size, is easily recombinantly expressed and has a low production cost, can be used alone or as a drug delivery system to carry relevant drugs, and has very wide prospects and important significance in fields such as drug application and clinical diagnosis.
Absstract of: WO2025080942A1
The present disclosure provides proteasome inhibitors of Formula (I), useful in treating cancer, such as multiple myeloma and mantle cell lymphoma.
Absstract of: US2025120947A1
The present invention generally relates to sensitizer compounds and their use to sensitize cancer and/or pre-cancerous cells of certain cancers to treatment with certain resistance-prone therapeutics used in cancer therapy. In embodiments, the conjugates of particular esters or amides of Near Infrared Dyes, are used as sensitizers to avoid or overcome therapeutic resistance once formed. In embodiments, the sensitizers include conjugates with Cisplatin, Simvastatin, Artemisinin, platin-based compounds or statins. In embodiments, the resistance prone cancer therapeutics include cisplatin, gemcitabine, doxorubicin, paclitaxel, docetaxel, and platin-based compounds. These may be administered in combination with the sensitizer, or the sensitizer itself may comprise an therapeutci-derived moiety conjugated to the sensitizer, for example as is the case for dye-CIS conjugated sensitizers. Alternatively, the sensitizer may be co-administered with one or more therapeutic. Embodiments of the invention may advantageously be used in cancers that have a tendency to develop resistance to such cancer therapeutics and/or to form metastases, including e.g. lung, pancreatic, prostate, testicular, ovarian, cervical, bladder, breast, head and neck, esophageal, and stomach, cancers, germ cell tumors, lymphomas and other cancers.
Absstract of: US2025121001A1
A method of enhancing embryo implantation in a subject is disclosed which comprises administering to the uterine cavity of the subject a formulation comprising copper and/or zinc in an amount effective to stimulate endometrial production of leukaemia inhibitory factor (LIF) and/or vascular endothelial growth factor (VEGF). Alternatively, a device may be inserted into the uterine cavity of the subject, wherein the device comprises copper and/or zinc, for a period of time that is effective to stimulate endometrial production of LIF and/or VEGF. The method is suitable for use with women undergoing treatment by any of the assisted reproductive technologies, such as those involving the transfer of embryos such as in vitro fertilisation (IVF) and variants including IVF-ICSI (intracytoplasmic sperm injection) and in vitro maturation (IVM) treatments, as well as intrauterine-insemination (IUI) therapy. However, the method is also applicable for women wanting to improve their prospects of pregnancy through natural conception.
Absstract of: US2025122300A1
Isolated anti-human CD45RC antibodies or binding fragments thereof, nucleic acids and expression vector encoding the same, compositions including the same, and uses thereof as medicaments, including for the prevention and/or treatment of CD45RChigh-related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, and lymphoma or cancer), in particular for use in preventing and/or treating graft-versus-host disease (GVHD).
Absstract of: EP4538294A1
The present application relates to a multi-specific binding molecule targeting BCMA, GPRC5D and a T cell receptor. In particular, the present application discloses a multi-specific antibody against BCMA, GPRC5D and CD3, which can bind to a tumor surface antigen while activating T cells, thereby promoting the specific killing of tumor cells, in particular BCMA-positive or GPRC5D-positive multiple myeloma, by T cells. The present application further provides a preparation method for and the application of the multi-specific binding molecule.
Absstract of: WO2023101445A1
The present invention relates to a composition for diagnosing malignant lymphoma of a dog, and was completed by discovering a biomarker capable of diagnosing malignant lymphoma with high accuracy and sensitivity through qualitative and quantitative analysis of plasma proteins of the dog. Specifically, the present inventors performed proteomic analysis using high-resolution mass spectrometry on plasma proteins of the dog suffering from malignant lymphoma, and selected biomarkers showing significant expression differences compared to normal controls. It was confirmed that a malignant lymphoma diagnosis model established using the selected biomarkers can diagnose malignant lymphoma with high specificity, sensitivity, and accuracy. Therefore, the present invention is a non-invasive method using a small amount of blood, thereby enabling risk prediction and early diagnosis of malignant lymphoma of a companion dog, and thus, it is expected to contribute not only to preserving the health of the companion dog and reducing the burden of medical expenses of a guardian, but also to improving the quality of veterinary consulting.
Absstract of: WO2025076428A1
The present disclosure relates to a method for classifying a subject diagnosed with follicular lymphoma (FL) into 7 FL subtypes (FL1-FL7) and related methods of treating a subject diagnosed with FL. The present disclosure further includes related compositions, e.g., isolated probes and primers, as well as kits and arrays comprising same. A therapy guidance software tool is also disclosed.
Absstract of: WO2025076501A1
Disclosed herein are high throughput synthetic methods for the deliberate and prospective discovery of molecular glues which can be used to form composite protein-ligand surfaces that facilitate interfacial binding to other proteins over dispersed surfaces. In particular, this application discloses a high throughput approach using sulfur(VI) fluoride exchange (SuFEx) transformations and N-hydroxysuccinimide (NHS)-ester derived amide couplings to prospectively repurpose known ligands for a prolein-of-interest into degraders and compounds capable of inducing proximity to other proteins. Disclosed herein are methods of developing known ligands of a target protein into degraders of the target proteins. Further disclosed are methods of developing novel small molecule chromatin-competitive inhibitors of the eleven nineteen leukemia (ENL) YEATS domain into effective degraders of ENL.
Absstract of: WO2025073216A1
Provided are a novel DNA methylation marker TAGMe-5 for tumor identification and a use thereof. The tumor marker TAGMe-5 shows a significant DNA methylation difference in para-carcinoma tissues and carcinoma tissues, the difference has remarkable statistical significance, and the difference is shown in a plurality of tumors such as solid tumors and non-solid tumors. The solid tumors comprise lung cancer, liver cancer, prostate cancer, cervical cancer, endometrial cancer, urothelial carcinoma, a biliary tract tumor, etc. The non-solid tumors comprise a blood system tumor, lymphoma, etc. Therefore, the tumor marker can be used for screening, molecular diagnosis, prognosis, and therapeutic effect evaluation for clinical multi-tumors (Pan-cancer).
Absstract of: WO2025076472A1
Provided herein are methods and uses of combination therapies involving GPRC5D- targeted cell therapy comprising chimeric antigen receptors (CARs), which contain extracellular antigen-binding domains that bind to G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), and a combination agent, e.g. an immunomodulatory compound, for treating subjects with cancers such as multiple myeloma, and related methods, uses, and articles of manufacture.
Absstract of: US2025115665A1
Provided are methods of clinical treatment of Diffuse Large B-cell Lymphoma (for example, relapsed and/or refractory Diffuse Large B-cell Lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with lenalidomide or ibrutinib and lenalidomide.
Absstract of: WO2025076471A2
Disclosed are chimeric antigen receptors that target glycoprotein A repetitions predominant (GARP) and methods of their use in the treatment of cancer including, but not limited to breast cancer, bladder cancer, glioblastoma, or leukemia or other malignancies characterized with GARP+ Tregs.
Absstract of: US2025109198A1
Described herein are approved products and methods of using approved products for treating relapsed or refractory multiple myeloma in a patient. Also described herein are methods of selling or offering for sale an approved product.
Absstract of: WO2025068340A1
The present invention relates to a method for predicting the survival time of a patient suffering from an Acute Myeloid Leukemia (AML). In this study, the inventors used conditional Jam-3-deficient mice crossed with iMLL-AF9 leukemia model. They found that Jam-3-deficiency rewired the transcriptional program of leukemia initiating cells (LIC) with upregulation of genes belonging to AP-l/TNF-α pathways. Transposition of results to human allowed to determine a new prognosis score called ATIC for AP-l/TNF-α Initiating Cells, complementary and distinct from the LSC17 score. Thus, the invention relates to a method for predicting the survival time of a patient suffering from an Acute Myeloid Leukemia (AML) based on the determination in a sample obtained from the patient of the expression levels of at least 7 genes selected in the group consisting in: JAM3, DUSP1, JUN, IER2, DUSP2, RGS1, H2BC8, PTGS2, NFKBID, PPP1R15A, NFKBIZ, ZFP36, SNORA28, TPT1, KLF2, BTG2, JUNB, JUNE), ATF3, UBC, SKIL, TAF7, SLFN12L, NR4A1, CHST2, GASS, SNORA31, HES1, EGR3, RPS13, PMAIP1, RHOB, MYL9, ZNF699, ZNF101, FOS, FJX1, RPP25L, HEY1, PTMA, GIMAP4, EFCAB11, FOSE, CD14, CCL4, CCL3, PF4, OSM, CD69, ITGA2B, VWF, MYCN and F2RL2.
Absstract of: US2025110131A1
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T-cell lymphoma that can develop around breast implants. The disclosure is directed towards devices and methods for diagnose BIA-ALCL from the seroma (fluid) surrounding the implant using a lateral flow assay (LFA) detecting CD30 and/or one or more cytokines known to be produced by tumor cells in BIA-ALCL.
Absstract of: US2025108043A1
Provided are systems and methods for continuously administering to a subject in need of treatment a formulation comprising an immunomodulatory imide compound. In some embodiments, the method are for use in treating multiple myeloma, transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes, mantle cell lymphoma, hematologic cancers, or solid tumor cancers.
Absstract of: WO2025067468A1
Described herein are Casitas B-lineage lymphoma (Cbl) inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or condition associated with Cbl-b activity, such as cancers.
Absstract of: WO2025065747A1
Disclosed is an application of a CSF1R inhibitor in the preparation of an NK/T cell lymphoma treatment drug. Further disclosed are a use as an NK/T cell lymphoma marker, a use of a CSF1 detection reagent in the preparation of an NK/T cell lymphoma prognosis kit, and a use of the CSF1 detection reagent in the preparation of an NK/T cell lymphoma primary screening kit. The present invention can be promoted and applied to primary screening, prognosis and treatment of clinical NK/T cell lymphoma patients.
Absstract of: WO2025071406A1
The invention relates to the field of leukemia/lymphoma diagnosis, more specifically to the detection of MRD in bone marrow, blood and other fluids and tissues from patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma (T-ALL/T-LBL). Provided is a reagent composition for the cytometric detection of minimal residual disease (MRD) in T-ALL and/or T-LBL, the reagent composition comprising a panel of at least four antibodies conjugated to a detectable label, the panel comprising antibodies against markers NKp80, CD16, cyCD3 and smCD3.
Absstract of: AU2025201932A1
Abstract The present disclosure provides compositions and methods useful for treating Glioblastoma Multiforme (GBM), e.g., compositions comprising virus-like particles (VLPs) comprising Moloney Murine leukemia virus (MMLV) core proteins and the human cytomegalovirus epitopes, gB and pp65, formulated with GM-CSF, which, at dose of at least 10 pg gB/pp65Gag, reverse dysregulation of anti-HCMV immunity in GBM patients. 21570040_1 (GHMatters) P117888.AU.1
Absstract of: WO2025071306A1
The present invention relates to a pharmaceutical composition for treating cancer in which an elF4A inhibitor and at least one of a BCL-2 inhibitor or a selective export protein (XPO-1) inhibitor are used in a combination regimen. The present invention relates to a pharmaceutical composition for treating cancer, wherein the elF4A inhibitor is one selected from the group consisting of silvestrol, CR-1-3B, zotatifin, rohinitib, didesmethylrocaglamide, and episylvestrol, and used in a combination regimen with at least one of a BCL-2 inhibitor or a selective nuclear export protein inhibitor.
Absstract of: WO2025072081A1
Provided herein are systems, kits, and methods for generating an enriched T cell population from an initial peripheral blood mononuclear cell (PBMC) population using at least two types of cell-binding reagents: (e.g., particles conjugated to CD32, CD19, CD244, or CD25 binding agents), where the enriched T cell population is: i) enriched for desired T-cells (e.g., early memory T cells and naïve T cells), and ii) depleted in normal and malignant non-desired cells selected from: CD25hi regulatory T-cells (Tregs), CD25hi CLL cells, CD244 T-cells, CD32+ monocytes, CD32+ myeloid leukemia cells, CD32 basophils, CD19+ and/or CD32+ B cells, CD244+ natural killer (NK) cells, and myeloid cells). In certain embodiments, the enriched T cell populations are used for generating a population of chimeric antigen receptor (CAR) T-cells, T-cell receptor-engineered T cells, or Tumor-infiltrating T lymphocyte (ITL) products.
Absstract of: WO2025072692A1
Compositions for treating hematological conditions such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) are provided. In particular, a population of CD8+ T lymphocytes with cytotoxic activity against leukemia cells is provided, as well as methods of isolating and enriching such cells for therapeutic applications.
Nº publicación: WO2025072637A1 03/04/2025
Applicant:
THE REGENTS OF THE UNIV OF MICHIGAN [US]
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Absstract of: WO2025072637A1
Disclosed herein is a class of small-molecules having oxygenated heterocyclic ring structure. Compounds disclosed herein are lysine demthylase-1 (LSD-1) inhibitors, and accordingly, also disclosed herein is the use the compounds as therapeutics for the treatment of hematological disorders (e.g., sickle cell disease (SCD), β-thalassemia), cancer (e.g., acute myeloid leukemia (AML), multiple myeloma, biliary tract cancer, non-small cell lung cancer (NSCLC), chronic lymphocytic leukemia, advanced solid tumor, advanced malignancies), and/or a neurological disorder (e.g., Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Parkinson disease (PD), Schizophrenia, Huntington disease (HD)), a metabolic disorder (e.g., type-2 diabetes (T2D), obesity) and other conditions related to LSD-1 activity (e.g., mild to moderate Alzheimer's disease, myocardial fibrosis, autism, complex neurodevelopmental diseases).
BOPI
Electronic site
